Form 4: Leap Therapeutics Executive Douglas Onsi Reports Share Transactions

Douglas Onsi, a key executive at Leap Therapeutics, reported the exercise of a warrant and changes in beneficial ownership of common stock.

Summary

• Douglas Onsi, a director and officer at Leap Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On November 13, 2024, Nine Capital Partners, LLC, where Onsi is a managing member, exercised a warrant to purchase 2,136 shares of Leap Therapeutics common stock at $2.82 per share.
• Onsi's reported beneficial ownership includes shares held directly and indirectly through Nine Capital Partners, HealthCare Ventures IX, L.P., and the HCV VIII Trust.
• Onsi disclaims beneficial ownership of the shares held by these entities except to the extent of his proportionate pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing and does not indicate any positive or negative sentiment. It simply reports a transaction.

Industry Context

Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.

Comparison to Industry Standards

• Form 4 filings are a common practice for all publicly traded companies in the US, ensuring transparency of insider trading.
• The reported transactions are typical for executives who hold stock options or warrants as part of their compensation.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• The transaction has a minimal impact on the company's overall financial position.

Key Dates

Keywords

Form 4, Beneficial Ownership, Leap Therapeutics, Douglas Onsi, Warrant Exercise, Share Transaction, LPTX, Nine Capital Partners, HealthCare Ventures